Challenges of insulin-like growth factor-1 testing
Rongrong HuangJunyan ShiRuhan WeiJieli Lia Department of Pathology and Immunology,Baylor College of Medicine,Houston,TX,USAb Department of Pathology and Laboratory Medicine,Harris Health System Ben Taub Hospital,Houston,TX,USAc Department of Pathology and Laboratory Medicine,Vancouver General Hospital,Vancouver Coastal Health,Vancouver,British Columbia,Canadad Department of Pathology and Laboratory Medicine,University of British Columbia,Vancouver,British Columbia,Canadae Department of Pathology,Duke University School of Medicine,Durham,NC,USAf Department of Pathology,Wexner Medical Center,The Ohio State University,Columbus,OH,USA
DOI: https://doi.org/10.1080/10408363.2024.2306804
IF: 7.721
2024-02-07
Critical Reviews in Clinical Laboratory Sciences
Abstract:Insulin-like growth factor 1 (IGF-1), primarily synthesized in the liver, was initially discovered due to its capacity to replicate the metabolic effects of insulin. Subsequently, it emerged as a key regulator of the actions of growth hormone (GH), managing critical processes like cell proliferation, differentiation, and apoptosis. Notably, IGF-1 displays a longer half-life compared to GH, making it less susceptible to factors that may affect GH concentrations. Consequently, the measurement of IGF-1 proves to be more specific and sensitive when diagnosing conditions such as acromegaly or GH deficiency. The recognition of the existence of IGFBPs and their potential to interfere with IGF-1 immunoassays urged the implementation of various techniques to moderate this issue and provide accurate IGF-1 results. Additionally, in response to the limitations associated with IGF-1 immunoassays and the occurrence of discordant IGF-1 results, modern mass spectrometric methods were developed to facilitate the quantification of IGF-1 levels. Taking advantage of their ability to minimize the interference caused by IGF-1 variants, mass spectrometric methods offer the capacity to deliver robust, reliable, and accurate IGF-1 results, relying on the precision of mass measurements. This also enables the potential detection of pathogenic mutations through protein sequence analysis. However, despite the analytical challenges, the discordance in IGF-1 reference intervals can be attributed to a multitude of factors, potentially leading to distinct interpretations of results. The establishment of reference intervals for each assay is a demanding task, and it requires nationwide multicenter collaboration among laboratorians, clinicians, and assay manufacturers to achieve this common goal in a cost-effective and resource-efficient manner. In this comprehensive review, we examine the challenges associated with the standardization of IGF-1 measurement methods, the minimization of pre-analytical factors, and the harmonization of reference intervals. Particular emphasis will be placed on the development of IGF-1 measurement techniques using "top-down" or "bottom-up" mass spectrometric methods.
medical laboratory technology